Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence

This is a phase 2 study, single-arm study of adjuvant combination therapy with Sacituzumab Govitecan and Nivolumab in patients with muscle-invasive urothelial carcinoma of the bladder, ureter, or upper tract, who are high risk for cancer recurrence post curative-intent surgery based on surgical pathology.

Trial Details

NCT ID
NCT06682728
Phase
PHASE2
Sponsor
University of California, Irvine
Status
RECRUITING
Cancer Type
Urothelial Carcinoma Bladder Cancer
Interventions
  • Sacituzumab Govitecan (SG)
  • Nivolumab
Locations (sample)
  • Orange, California, United States|33.78779,-117.85311

Key Eligibility Criteria

  • Age ≥ 18 years at the time of study consent.
  • ECOG Performance Status of 0, 1 or 2 (see Appendix A).
  • Histologically confirmed muscle-invasive UC originating in the bladder, ureter, or renal pelvis. Variant histology, except small cell carcinoma, is…
  • Underwent curative-intent surgery (i.e. RC or nephroureterectomy), performed within 180 days prior to study treatment initiation.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Urothelial Carcinoma Bladder Cancer Trials on Trialify →